scholarly journals Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats

2002 ◽  
Vol 135 (4) ◽  
pp. 961-968 ◽  
Author(s):  
Stevo Mirkovic ◽  
Anne-Marie L Seymour ◽  
Andrew Fenning ◽  
Anna Strachan ◽  
Solomon B Margolin ◽  
...  
1999 ◽  
Vol 5 (3) ◽  
pp. 77
Author(s):  
Fumitaka Kuwahara ◽  
Hisashi Kai ◽  
Tsuyoshi Nagata ◽  
Rei Shibata ◽  
Hiroshi Niiyama ◽  
...  

2011 ◽  
Vol 17 (2) ◽  
pp. 48 ◽  
Author(s):  
Eun Ho Choo ◽  
Sang-Hyun Ihm ◽  
Ok-Ran Kim ◽  
Sung-Won Jang ◽  
Chan-Seok Park ◽  
...  

Hypertension ◽  
1991 ◽  
Vol 18 (2) ◽  
pp. 148-157 ◽  
Author(s):  
M Pahor ◽  
R Bernabei ◽  
A Sgadari ◽  
G Gambassi ◽  
P Lo Giudice ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Lin-hua Deng ◽  
Lan Li ◽  
You Zhai ◽  
Sarhene Michael ◽  
Chun-yang Yang ◽  
...  

Tianma Gouteng Decoction (TGD) is widely used in traditional Chinese medicine for the treatment of hypertension and its related complications, but its mechanisms remain incompletely defined. We now aim to assess the protective effect of TGD against cardiovascular damage and to investigate its characteristics and underlying mechanisms. Blood pressure was determined in TGD-treated spontaneously hypertensive rats (SHR) by noninvasive measurements. Echocardiography was performed to assess cardiac function and structure and sirius red staining to evaluate cardiac fibrosis, and the degree of vascular remodeling was evaluated. Additionally, vasoconstriction and relaxation factor expression changes were examined by means of ELISA. Protein expression changes were verified by western blot. Compared with untreated SHR, TGD-treated SHR exhibited cardiovascular traits more akin to those of the normotensive Wistar Kyoto (WKY) rats. That is, they had lower diastolic blood pressure, systolic blood pressure and mean BP, and increased expression of vasodilation factor. We also found that TGD reduces ventricular and vascular remodeling and improves cardiac function in SHR. Finally, we tested the antiapoptosis effect TGD exerts in SHR, ostensibly by upregulating the expression of OPG, TRAIL, and death receptor 5 (DR5) and downregulating caspases 8, 7, and 3. TRAIL may also exert antiapoptotic and prosurvival effects by upregulating AKT expression. Therefore, TGD may reverse cardiovascular remodeling in SHR by upregulating the expression of OPG and TRAIL, upregulating AKT, and inhibiting apoptosis, at least in part. For the first time, we have shown that OPG and TRAIL play complimentary cardioprotective roles in SHR.


Life Sciences ◽  
2013 ◽  
Vol 92 (24-26) ◽  
pp. 1180-1185 ◽  
Author(s):  
Maimaiti Yisireyili ◽  
Hidehisa Shimizu ◽  
Shinichi Saito ◽  
Atsushi Enomoto ◽  
Fuyuhiko Nishijima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document